Advancements and Future Directions of Dual‐Target Chimeric Antigen Receptor T‐Cell Therapy in Preclinical and Clinical Studies
Journal of Immunology Research · 2025-01 · 2025 (1)
DOI: 10.1155/jimr/5845167 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Immunology Research, online erschienen am 15.01.2025. Verfasst von Chenyun Zhang und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Tsinghua, Beijing, China. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Neoplasms, T-Lymphocytes. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In recent years, chimeric antigen receptor T‐cell (CAR‐T) therapy has made groundbreaking progress in the treatment of various cancer types, particularly hematological malignancies. In the meantime, various preclinical and clinical studies have extensively explored dual‐target CAR‐T therapies which can be designed to recognize two antigens simultaneously based on the immunophenotype of tumor cells. Compared with single‐target CAR‐T approach, dual‐target CAR‐T therapies demonstrate varying degrees of superior antitumor CAR effects, prevent antigen escape and relapse, reduce on‐target off‐tumor effects, and ensure durable responses in different types of cancer. These advantages highlight the potential future prospects in this field, showing varying degrees of advancement in preclinical and clinical studies. Herein, we aimed to review different dual‐target CAR‐T studies conducted on a wide range of tumor models, summarizing the selection of target combinations, the efficacy and safety demonstrated in preclinical and clinical settings, the existing limitations, and the potential future directions of this promising therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of Tsinghua, Beijing, China.
- Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Chenyun Zhang, Haizhou Liu
Zitieren
APA
Zhang, C., & Liu, H. (2025). Advancements and Future Directions of Dual‐Target Chimeric Antigen Receptor T‐Cell Therapy in Preclinical and Clinical Studies. Journal of Immunology Research, 2025(1). https://doi.org/10.1155/jimr/5845167
Vancouver
Zhang C, Liu H. Advancements and Future Directions of Dual‐Target Chimeric Antigen Receptor T‐Cell Therapy in Preclinical and Clinical Studies. Journal of Immunology Research. 2025;2025(1). doi:10.1155/jimr/5845167
BibTeX
@article{Zhang2025,
author = {Zhang, Chenyun and Liu, Haizhou},
title = {Advancements and Future Directions of Dual‐Target Chimeric Antigen Receptor T‐Cell Therapy in Preclinical and Clinical Studies},
journal = {Journal of Immunology Research},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/jimr/5845167}
}
EUVIMED